Clinical Trials Browser

Phase 1/2 × Efficacy × Immune Checkpoint Inhibitors × Clear all

NCT05325684 2022-04-13

PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer

Phase 1/2 Unknown

Efficacy